Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.42 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4014373 | 0.93 | HTT (0.49) | HTTEPHX2 | |
| SCHEMBL4017873 | 0.88 | HTT (0.55) | HTTEPHX2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4017433 | 0.86 | HTT (0.52) | HTTEPHX2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4015218 | 0.85 | HTT (0.51) | HTTEPHX2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4019401 | 0.85 | TAS1R3 (0.53) | HTTEPHX2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4017033 | 0.84 | TAS1R3 (0.61) | HTTTAS1R3TAS1R1TAS1R2KMT2A | |
| SCHEMBL4016100 | 0.82 | TRPV1 (0.51) | HTTEPHX2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL12860202 | 0.82 | HTT (0.38) | HTTTAS1R3TAS1R1TAS1R2CYP11B1 | |
| SCHEMBL1151423 | 0.82 | HTT (0.38) | HTTTAS1R3TAS1R1TAS1R2CYP11B1 | |
| SCHEMBL12860292 | 0.82 | HTT (0.38) | HTTTAS1R3TAS1R1TAS1R2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598417-B2 | Analgesics; muscular disorders; diarrhea | ALLERGAN, INC. (US) | 2009-10-06 | — | — | US | claimed |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN, INC. | 2008-10-16 | — | — | US | claimed |
| US-7598417-B2 | Analgesics; muscular disorders; diarrhea | ALLERGAN, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598417-B2 | Analgesics; muscular disorders; diarrhea | ALLERGAN, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598417-B2 | Analgesics; muscular disorders; diarrhea | ALLERGAN, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2A, ADRA2C | HTT 3760/4885EPHX2 370/4885TAS1R3 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.